Pirbright vaccine study provides hope for protection against a major cause of severe respiratory disease in babies
Posted: 13 August, 2015
A new type of vectored vaccine for respiratory syncytial virus (RSV), a virus that causes respiratory disease in humans, has been shown by scientists at Pirbright to provide immunity against a closely related virus in calves, giving strong evidence that a similar type of vaccine could work in humans.